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ARTICLE
Mitochondrial Haplogroup N9a Confers Resistance against Type 2
Diabetes in Asians
Noriyuki Fuku,* Kyong Soo Park,* Yoshiji Yamada, Yutaka Nishigaki, Young Min Cho,
Hitoshi Matsuo, Tomonori Segawa, Sachiro Watanabe, Kimihiko Kato, Kiyoshi Yokoi,
Yoshinori Nozawa, Hong Kyu Lee, and Masashi Tanaka
Because mitochondria play pivotal roles in both insulin secretion from the pancreatic b cells and insulin resistance of
skeletal muscles, we performed a large-scale association study to identify mitochondrial haplogroups that may confer
resistance against or susceptibility to type 2 diabetes mellitus (T2DM). The study population comprised 2,906 unrelated
Japanese individuals, including 1,289 patients with T2DM and 1,617 controls, and 1,365 unrelated Korean individuals,
including 732 patients with T2DM and 633 controls. The genotypes for 25 polymorphisms in the coding region of the
mitochondrial genome were determined, and the haplotypes were classiﬁed into 10 major haplogroups (i.e., F, B, A, N9a,
M7a, M7b, G, D4a, D4b, and D5). Multivariate logistic-regression analysis with adjustment for age and sex revealed that
the mitochondrial haplogroup N9a was signiﬁcantly associated with resistance against T2DM ( ) with an oddsPp .0002
ratio of 0.55 (95% conﬁdence interval 0.40–0.75). Even in the modern environment, which is often characterized by
satiety and physical inactivity, this haplogroup might confer resistance against T2DM.
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Type 2 diabetes mellitus (T2DM [MIM 125853]) is a com-
plex disorder characterized by impaired insulin secretion
from pancreatic b cells and reduced insulin action or in-
sulin resistance in the peripheral tissue. There is a grow-
ing body of evidence indicating that mitochondrial dys-
function plays a pivotal role in b-cell dysfunction, as well
as in insulin resistance. Mitochondrial metabolism,which
produces ATP, is essential in insulin secretion through
metabolism-secretion coupling.1 A pancreatic b-cell line
lacking mitochondrial function exhibits impaired insulin
secretion,2 and mice with pancreatic b-cell–speciﬁc knock-
out of mitochondrial transcription factor Tfam show a
diabetic phenotype with severe mtDNA depletion.3 De-
creased capacity of the mitochondrial oxidative phos-
phorylation (OXPHOS) is associated with the insulin re-
sistance found in aged people and in offspring of in-
dividuals with T2DM.4,5 Microarray studies have shown
that insulin resistance and T2DM are associated with de-
creased expression of genes related to OXPHOS in the skel-
etal muscle.6,7 Therefore, mitochondrial dysfunction can
explain not only impaired insulin secretion but also re-
duced insulin action.
Proteins composing the mitochondrion are encoded by
both nuclear DNA andmtDNA. The latter encodes 13 sub-
units of the OXPHOS machinery and also encodes 2 ri-
bosomal RNA (rRNA) and 22 tRNA genes essential for the
translation process in mitochondria.8 There are many
lines of evidence indicating that mtDNA is responsible for
the pathogenesis of diabetes. A point mutation at nucle-
otide position 3243 in mitochondrial tRNA-Leu (UUR) is
well known to cause maternally inherited diabetes and
deafness, as well as mitochondrial myopathy, encepha-
lopathy, lactic acidosis, and strokelike (MELAS) episodes
in patients with high mutant loads.1 However, it remains
questionable whether mitochondrial dysfunction orig-
inating from common mtDNA polymorphisms is respon-
sible for T2DM. In this regard, it should be noted that
many epidemiologic studies have reported a maternal
excess in the transmission of T2DM.9,10 In addition, a
control-region polymorphism, such as the 16189TrC sub-
stitution in the noncoding region, is known to be asso-
ciated with insulin resistance, obesity, and diabetes in
both Europeans11 and Asians.12,13 A meta-analysis of Eu-
ropean studies, however, has indicated that genetic vari-
ation of the 16184–16193 poly-C tract is unlikely to have
a major role in the cause of T2DM.14
The geographic region–speciﬁc variations of mtDNA
haplogroups are now known to have been formed by nat-
ural selection, possibly to allow habitation in cold climat-
ic environments.15,16 Although mtDNA variations might
have permitted our ancestors to adapt to more-northern
or colder climates, they are also suggested to play a det-
rimental role in modern human diseases related to bio-
energetics or mitochondrial dysfunction.15–17 Therefore,
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some mtDNA haplogroup might actually confer suscep-
tibility to T2DM. It has been very recently reported that
there is no evidence of association between common
mtDNA polymorphisms and T2DM, at least not in Euro-
peans.18 Since Asians have different mtDNA haplogroups
and since T2DM is the result of complex interactions be-
tween genes and the environment, the above ﬁnding can-
not be extended to the Asian populations. In the present
study, we performed a large-scale association study on
T2DM and 10major haplogroups in both Japan andKorea,
on the basis of comprehensive analysis of polymorphisms
in the coding region of the mitochondrial genome.
Material and Methods
Study Population
The study population comprised 2,906 Japanese and 1,365 Ko-
rean subjects. Unrelated Japanese individuals (1,938men and 968
women) aged 40 years were enrolled from the population of
individuals who had either visited outpatient clinics of or been
admitted to one of the participating hospitals (Gifu Prefectural
Gifu, Tajimi, and Gero Hotspring Hospitals) between October
2002 and March 2005. The patients with T2DM had a fasting
plasma glucose (FPG) concentration of 7.0 mmol/liter (126
mg/dl) and/or a blood glycosylated hemoglobin (HbA1c) level
of 6.5% or were taking antidiabetes medication. T2DM was de-
ﬁned according to the criteria accepted by the World Health Or-
ganization. Members of families with diabetes mellitus and sib
pairs with this condition were excluded from the study. Although
some of the patients with T2DM who were taking antidiabetes
medication had a normal HbA1c level or a normal FPG concen-
tration when the blood samples were obtained, they had exhib-
ited abnormally high levels of HbA1c and FPG before starting
the antidiabetes medication. We excluded the patients with type
1 diabetes who required insulin within 1 year after the initial
diagnosis or episode of diabetic ketoacidosis.
On the basis of these criteria, 1,289 subjects (890 men and 399
women) in the Japanese study population were given diagnoses
of T2DM. The control group comprised the remaining 1,617 in-
dividuals (1,048 men and 569 women) in the Japanese study
population who visited the outpatient clinics of the participating
hospitals for an annual health checkup. They had an FPG con-
centration of !6.1 mmol/liter (110 mg/dl) and a blood HbA1c
level of !5.6%, and they had no history of T2DM or of taking
antidiabetes medication. The study protocol was approved by the
Committee on the Ethics of Human Research of Gifu Interna-
tional Institute of Biotechnology, and written informed consent
was obtained from each participant.
Unrelated Korean patients with T2DM were enrolled from the
Diabetes Clinic of Seoul National University Hospital ( ).np 732
Control subjects without diabetes were recruited from the group
of individuals who had visited Seoul National UniversityHospital
for a routine annual checkup ( ). T2DM was diagnosednp 633
according to World Health Organization criteria. Subjects with
positive glutamic acid decarboxylase antibodies were excluded.
The control subjects without diabetes were selected according to
the following criteria: age 60 years, no past history of diabetes,
no diabetes in ﬁrst-degree relatives, an FPG concentration of !6.1
mmol/liter, and an HbA1c value of !5.8%. The Institutional Re-
view Board of the Clinical Research Institute in Seoul National
University Hospital approved the study protocol, and written in-
formed consent for genetic analysis was obtained from each sub-
ject. All study subjects were examined in the morning after an
overnight fast. The clinical characteristics of Japanese and Korean
subjects are shown in tables 1 and 2, respectively.
Selection of Mitochondrial Polymorphisms for Haplogroup
Classiﬁcation
In earlier studies, we aimed to identify mitochondrial SNPs
(mtSNPs) associated with age-related conditions, such as longev-
ity,19 Parkinson disease,20,21 and Alzheimer disease, as well as those
related to energy metabolism—such as obesity,22,23 thinness, and
T2DM22—or to atherosclerosis. For this purpose, we sequenced
the entire mitochondrial genomes of 672 individuals belonging
to seven different groups, with 96 individuals in each group—
namely, centenarians, patients with Parkinson disease, patients
with Alzheimer disease, young obese or nonobese males, and pa-
tients with T2DM with or without severe vascular involvement.24
From our ﬁndings, we constructed a human mitochondrial ge-
nome polymorphism database (mtSNP). On the basis of these
mtSNP data, we have developed a comprehensive mtSNP analysis
system that uses ﬂuorescent beads.
By using our mtSNP database and a phylogenetic tree of the
Japanese,24 we selected 149 polymorphic sites that have been use-
ful for classiﬁcation of mitochondrial haplogroups. We selected
a further 25 mtSNPs that deﬁne 10 major haplogroups (i.e., F, B,
A, N9a, M7a, M7b, G, D4a, D4b, and D5) found in this area (ta-
ble 3). Then, we examined the relationship between these hap-
logroups and T2DM in the 4,271 participants.
Genotyping of Polymorphisms
Venous blood (7 ml) was collected from each subject into tubes
containing 50 mmol/liter EDTA (disodium salt), and genomic
DNA was isolated with the use of a commercial kit (Genomix
[Talent]). For amplifying mtDNA fragments, we performed 28-
plex PCR. The reaction mixture (25 ml) contained 1 ng of genomic
DNA, 5 pmol of each primer, 0.2 mmol/liter of each deoxynu-
cleoside triphosphate, 2 mmol/liter MgCl2, and 1 U of DNA poly-
merase (FastStart Taq DNA Polymerase [Roche Diagnostics]) in
the PCR buffer supplied by the manufacturer. The ampliﬁcation
protocol consisted of an initial denaturation at 95C for 10 min
followed by 40 cycles of denaturation at 94C for 20 s, annealing
at 60C for 30 s, and extension at 72C for 30 s, with a ﬁnal
extension at 72C for 7 min. The primers used are shown in table
4. Mitochondrial polymorphisms were determined with sequence-
speciﬁc oligonucleotide probes (G&GScience)byuseof suspension-
array technology (Luminex 100 [Luminex]). Themethodologyused
for genotyping was described in detail elsewhere.25 Probes used for
haplotyping are shown in tables 5 and 6. To conﬁrm the accuracy
of genotyping by thismethod,we subjected 91DNAsampleswhose
entire sequence of themitochondrial genomehadbeendetermined
by direct sequencing to the Luminex method. In each instance,
the genotype determined by the Luminex sequence-speciﬁc oli-
gonucleotide-hybridization assay system was identical to that de-
termined by direct sequencing.
Statistical Analysis
Quantitative clinical data were compared between patients with
diabetes and control individuals by use of the unpaired Student’s
t test. Qualitative data were compared using the x2 test. We per-
formed multivariate logistic-regression analysis to adjust for risk
Table 1. Characteristics of Japanese Patients with T2DM and Controls
Variable
All Women Men
T2DM
( )np 1,289
Controls
( )np 1,617 P
T2DM
( )np 399
Controls
( )np 569 P
T2DM
( )np 1,289
Controls
( )np 1,048 P
Age (years) 63.5  11.6 (25–92) 65.5  11.0 (18–95) !.0001 65.2  11.9 (26–90) 66.1  11.4 (18–95) .2290 62.7  11.3 (25–92) 65.2  10.8 (22–94) !.0001
Sex (% female/% male) 30.9/69.1 35.2/64.8 .0140 … … … … … …
BMI (kg/m2) 23.7  3.5 (13.2–42.6) 23.1  3.2 (13.6–34.2) !.0001 23.5  3.9 (13.2–39.4) 23.0  3.5 (13.6–34.2) .0270 23.8  3.3 (14.6–42.6) 23.2  3.0 (14.1–34.1) !.0001
Blood pressure (mmHg):
Systolic 146  27 (82–256) 142  26 (70–254) .0004 150  29 (88–256) 145  26 (89–254) .0200 145  26 (82–250) 141  25 (70–244) .0030
Diastolic 77  15 (30–166) 76  15 (31–146) .0420 77  15 (41–166) 76  15 (38–130) .1710 77  15 (30–132) 76  14 (31–146) .1300
Total cholesterol (mmol/liter) 5.21  1.01 (2.26–10.50) 5.24  .98 (2.60–9.02) .6470 5.50  1.15 (2.94–10.50) 5.43  1.02 (2.81–9.02) .4300 5.10  .93 (2.26–8.22) 5.12  .95 (2.60–8.87) .5630
Triglycerides (mmol/liter) 1.80  1.37 (.15–19.62) 1.58  1.04 (.13–16.90) !.0001 1.60  .93 (.44–7.90) 1.42  .84 (.29–5.54) .0170 1.94  1.50 (.15–19.62) 1.66  1.12 (.13–16.90) .0020
HDL cholesterol (mmol/liter) 1.26  .44 (.42–6.01) 1.33  .45 (.36–9.31) .0005 1.40  .43 (.62–3.64) 1.45  .38 (.65–3.22) .1440 1.20  .42 (.42–6.01) 1.26  .46 (.36–9.31) .0110
FPG (mmol/liter) 9.32  3.98 (3.80–33.72) 5.40  .76 (2.81–6.88) !.0001 9.44  3.94 (3.63–26.40) 5.41  .76 (3.25–6.88) !.0001 9.27  4.00 (3.80–33.72) 5.40  .76 (2.81–6.88) !.0001
HbA1c (%) 7.5  2.2 (4.4–16.4) 5.3  .4 (3.8–6.4) !.0001 7.9  2.3 (4.7–15.0) 5.2  .4 (3.8–6.4) !.0001 7.3  2.2 (4.4–16.4) 5.3  .4 (4.1–6.2) !.0001
NOTE.—Values are given as means  SDs, with ranges in parentheses.
Table 2. Characteristics of Korean Patients with T2DM and Controls
Variable
All Women Men
T2DM
( )np 732
Controls
( )np 633 P
T2DM
( )np 393
Controls
( )np 351 P
T2DM
( )np 339
Controls
( )np 282 P
Age (years) 59.5  9.4 (32–83) 64.7  3.6 (60–93) !.0001 60.0  9.1 (32–81) 64.4  3.4 (60–75) !.0001 59.0  11.3 (32–83) 64.9  3.8 (60–93) !.0001
Sex (% female/% male) 53.8/46.3 55.5/44.6 .5295 … … … … … …
BMI (kg/m2) 24.4  2.8 (16.5–35.0) 23.6  3.1 (14.7–32.8) !.0001 24.8  3.1 (16.5–35.0) 24.1  3.2 (14.7–32.8) .0026 24.1  2.5 (16.5–32.2) 23.0  2.8 (16.0–32.0) !.0001
Blood pressure (mmHg):
Systolic 135  20 (88–200) 128  20 (87–203) !.0001 135  21 (88–200) 129  20 (88–202) !.0001 135  19 (90–199) 128  19 (87–203) !.0001
Diastolic 81  12 (36–120) 80  11 (51–120) .0834 80  12 (40–120) 79  11 (51–120) .1017 82  12 (36–113) 81  11 (51–113) .4883
Total cholesterol (mmol/liter) 5.15  .97 (1.87–9.33) 4.98  .91 (2.47–8.74) .0011 5.29  .98 (2.68–9.33) 5.10  .89 (3.20–8.09) .0063 5.00  .94 (1.87–8.97) 4.84  .92 (2.47 –8.74) .0039
Triglycerides (mmol/liter) 1.88  1.28 (.36–12.23) 1.39  .70 (.36–5.83) !.0001 1.83  1.15 (.42–11.41) 1.42  .71 (.36–5.83) !.0001 1.93  1.43 (.36–12.23) 1.36  .68 (.50–4.92) !.0001
HDL cholesterol (mmol/liter) 1.23  .05 (.34–2.60) 1.20  .07 (.52–2.52) .1463 1.28  .05 (.60–2.60) 1.19  .05 (.60–2.26) !.0001 1.16  .02 (.34–2.31) 1.21  .09 (.52–2.52) .0497
FPG (mmol/liter) 8.54  2.53 (3.74–21.29) 4.96  0.49 (3.69–6.05) !.0001 8.61  2.55 (3.74–18.37) 4.95  .49 (3.85–6.05) !.0001 8.47  2.51 (3.96–21.29) 4.97  .50 (3.69–6.05) !.0001
HbA1c (%) 8.0  1.6 (4.2–14.4) 5.3  .3 (4.1–5.8) !.0001 8.1  1.6 (4.2–14.4) 5.3  .3 (4.1–5.8) !.0001 7.9  1.6 (4.4–14.3) 5.3  1.3 (4.1–5.8) !.0001
NOTE.—Values are given as means  SDs, with ranges in parentheses.
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Table 3. Polymorphic Sites Characteristic to 10 Major Haplogroups
Haplogroup Polymorphism(s)a
F 3970CrT (ND1: syn), 13928GrC (ND5: S531T), 10310GrA (ND3: syn)
B 8272 (9-bp deletion in noncoding region)
A 663ArG (12S rRNA), 8794CrT (ATP6: H90Y)
N9a 5231GrA (ND2: syn), 12358ArG (ND5: T8A), 12372GrA (ND5: syn)
M7a 2772CrT (16S rRNA), 4386TrC (tRNA-Gln)
M7b 4071CrT (ND1: syn), 4048GrA (ND1: D248N), 6680TrC (CO1: syn), 12811TrC (ND5: Y159H)
G 709GrA (12S rRNA), 4833ArG (ND2: T122A), 5108TrC (ND2: syn)
D4a 4883CrT (ND2: syn), 5178CrA (ND2: L237M), 3010GrA (16S rRNA), 14979TrC (Cytb: I78T),b 8473TrC (ATP8: syn)
D4b 4883CrT (ND2: syn), 5178CrA (ND2: L237M), 3010GrA (16S rRNA), 1382ArC (12Ss rRNA)
D5 4883CrT (ND2: syn), 5178CrA (ND2: L237M), 10397ArG (ND3: syn)
a syn p Synonymous mutation.
b Ctyb p cytochrome b.
Table 4. Primers Used for 28-Plex PCR
Fragment
Primer
Product
(bp)
Forward Reverse
Position Sequence (5′r3′) Position Sequence (5′r3′)
1 631 ACATCACCCCATAAACAAATAggTT 931 gCTTCTATTgACTTgggTTAATCg 301
2 1272 AgCAAACCCTgATgAAggCTAC 1781 TATATCTATTgCgCCAggTTTCAAT 510
3 2698 AgAggCgggCATgACACAgCA 3066 gATCACgTAggACTTTAATCgTTgA 369
4 3215 CCAAgAACAgggTTTgTTAAgATg 3569 ggggTTCATAgTAgAAgAgCgAT 355
5 3611 TCCTATTTATTCTAgCCACCTCTAg 3862 ATCATATTATggCCAAgggTCATg 252
6 3916 gAgTCCgAACTAgTCTCAggCT 4255 gAgggggAATgCTggAgATTgTA 340
7 4344 TCgAACCCATCCCTgAgAATCC 4577 gTTTATTTCTAggCCTACTCAggTAA 234
8 4623 TCCACAgAAgCTgCCATCAAgTA 4940 gAgAgTgAggAgAAggCTTACgT 318
9 4989 CAgCTACgCAAAATCTTAgCATAC 5257 TTgggCAAAAAgCCggTTAgCg 269
10 5921 ACTATTCTCTACAAACCACAAAgAC 6284 TgTTCAACCTgTTCCTgCTCCg 364
11 6535 CAgACCgCAACCTCAACACCAC 6807 gTgTgTCTACgTCTATTCCTACTg 273
12 7567 CTAAATCCTATATATCTTAATggCAC 7895 ATTggTggCCAATTgATTTgATggT 329
13 8153 ggggTATACTACggTCAATgCTC 8530 TCATTTTggTTCTCAgggTTTgTTAT 378
14 8628 CAAATATCTCATCAACAACCgACTA 8994 CAgggCTATTggTTgAATgAgTAg 367
15 9044 TAATTggAAgCgCCACCCTAgC 9414 ggCCTTggTATgTgCTTTCTCgT 371
16 9673 gAAACCAAATAATTCAAgCACTgCT 9987 ACCCTCATCAATAgATggAgACAT 315
17 10277 ACCCCTACCATgAgCCCTACAA 10515 gTgAgATggTAAATgCTAgTATAATAT 239
18 10983 TCACAATCATggCAAgCCAACgC 11280 AgTgAgCCTAgggTgTTgTgAg 298
19 11667 TCCAAACCCCCTgAAgCTTCAC 12137 AAgAggAAAACCCggTAATgATgT 471
20 12274 AggATAACAgCTATCCATTggTCT 12545 gTggCTCAgTgTCAgTTCgAgAT 272
21 12582 AgACTACTTCTCCATAATATTCATCC 12858 gTATAggATTgCTTgAATggCTgC 277
22 13077 CCACTCAAgCACTATAgTTgTAgC 13591 TCAgggAggTAgCgATgAgAgTA 515
23 13711 gCCggAAgCCTATTCgCAggAT 13980 CAggTTTTggCTCgTAAgAAggC 270
24 14217 CTAATCAACgCCCATAATCATACAA 14562 gTCgggTgTgTTATTATTCTgAATTT 346
25 14829 TCCgCATgATgAAACTTCggCT 15175 ggCCCCTCAgAATgATATTTggC 347
26 15257 gACAgTCCCACCCTCACACgAT 15600 gggACggATCggAgAATTgTgT 344
27 15696 TTCgCCCACTAAgCCAATCACTT 16037 TCCCCATgAAAgAACAgAgAATAgT 342
28 16421 ATATCCCgCACAAgAgTgCTACT 45 TggAgAgCTCCCgTgAgTggTT 194
factors, with T2DM as a dependent variable and independent
variables including age, sex ( and ), and ge-0p female 1pmale
notype of each mtSNP. The P value, odds ratio (OR), and 95% CI
were calculated. Unless indicated otherwise, a P value !.05 was
considered statistically signiﬁcant. Because of multiple compar-
isons of haplogroups, we applied Bonferroni correction. Since we
examined 10 haplogroups, we divided .05 by 10 to get .005. Thus,
a P value !.005 was considered statistically signiﬁcant.
Results
The characteristics of the 2,906 Japanese subjects are
shown in table 1. BMI, systolic and diastolic blood pres-
sure, serum concentration of triglycerides, FPG concen-
tration, and blood HbA1c level were signiﬁcantly higher
in patients with T2DM than in the controls ( ). Age,P ! .05
female:male ratio, and serum concentration of high-den-
sity lipoprotein (HDL) cholesterol were lower in the pa-
tients with diabetes than in the controls ( ).P ! .05
The characteristics of the 1,365 Korean subjects are
shown in table 2. The subjects with diabetes were signiﬁ-
cantly younger than the controls ( ). BMI, systolicP ! .05
blood pressure, serum concentrations of total cholesterol
and triglycerides, FPG concentration, and blood HbA1c
level were signiﬁcantly higher in the subjects with T2DM
than in the controls ( ).P ! .05
Ten commonmtDNA haplogroups accounted for 72.4%
and 68.2% of haplogroups in Japanese and Korean sub-
jects, respectively (table 7). When we combined Japanese
and Korean subjects, multivariate logistic-regression anal-
ysis with adjustment for age and sex (table 8) showed that
the subjects in the mitochondrial haplogroup N9a had a
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Table 5. Probe Set A for Haplotyping
Position Purposea Sequence (5′r3′)
681 a TgTAATCTTACTgAgAgCTAAT
681 b TgTAATCTTACTAAgAgCTAA
752 a CgTgCTTgATgCTTATTCCTTTTgA
856 a AAAgTTTAACTAggCTATACTA
1310 a CgTCTTTACgTggATACTTgC
1382 a ggCTATCgTAgTTgTCTggg
1442 a AACTAAgCACTCTATTCTCAgT
1647 p AggAgATTTCAACTTAACTTgA
2766 a gACCTgTgggTTTATTAggTA
3010 a ATCAggACATCCCAATggTg
3010 b ATCAggACATCCCgATggT
3027 a TgCAgCCgCTATCAAAgg
3458 p gCCATAAAACTCTTCACCAA
3496 a CCCTAAAACCCTCCACATc
3497 a CCTAAAACCCgTCACATC
3644 a ggATTgAgTAAgCggCT
3667 p TAgTTTgAgTTTgATgCTCA
4048 a CTAggAACAACATATAACgCACTC
4071 a gACAAAATATgTTgTATAgAgTTC
4071 b ACAAAATATgTTgTgTAgAgTTC
4086 a AAgTAgggTCTTggTAACAAAATA
4386 a ggTgTggTAggTggCAC
4386 b gggTgTgATAggTggC
4491 a CTggCCCAACCCATCATCTA
4505 a gTCATCTACTCTACTATCTTTg
4541 a CAgCgCTAAgCTCACACTgA
4833 a AggTTACCCAAggCgCCCCT
4895 a CCATCTCAATCATgTACCAA
4895 b ATCTCAATCATATACCAAATC
5108 a TTATCCTAACTACCACCgCA
5147 a CTCCAgCACCACAACC
5178 a TgAAACAAgATAACATgAC
5178 b CTgAAACAAgCTAACATgA
5231 a TCCCTAggAggCCTACCCCC
5964 a ATgCgCCgAATAgTAggTAT
6023 a TggCTggCCCAgTTCggCT
6086 a CgTCACAgCCCACgCATTTg
6086 b AgATTATTACAAATgCATgggCT
6253 a CTCgCATCTgCTACAgTggA
6689 a TggTTCTTTTTTTCCAgAgTAgT
6752 a CAATTggCTTCCTggggTT
6752 b CAATTggCTTCCTAgggTTT
8272 a CTCTAgAgggggTAgAggTggTgCT
8272 b TgggCTCTAgAggTggTgCTAT
8392 a gTAATTATggTgggTCATACg
8684 a ATCATTTgTTTTgAgATTAgTTT
8701 b AgTgTTgTgTATggTTATCAT
8731 p TgATTAAggATACTAgTATAAgAg
8784 a TAACCTCCTCgggCTCCTgC
8793 a CggACTCCTgCCCCACTCA
8794 a TggTgTAAATgAgTAAggCAgg
8829 a CAACTATCTATAAATCTAgCC
9123 a gATTTCTAggATAgTTAgTAgAAT
8794 a TggTgTAAATgAgTAAggCAgg
8829 a CAACTATCTATAAATCTAgCC
9123 a gATTTCTAggATAgTTAgTAgAAT
9219 p ATCACATgCCTATCATATAgTA
9296 a CTAATgACCTCCggTCTAgCC
9755 a TCAgAgTACTTCgAATCTCCC
9774 p ATgCCgTCggAAATggTgA
9950 a ATTTTgTAgATgTggTCTgACTA
10310 a ACTATTAgTggTAggTTAgTT
10397 a TACCAATTCAgCCCAgTCTAAT
10400 m ACTATATACCAATTCAgCTCAgT
10400 n ACTATATACCAATTCggTTCAgT
(continued)
Table 5. (continued)
Position Purposea Sequence (5′r3′)
11084 a gTggCTgTgAATgCTATAATTA
11215 a TACTTCCTATTCTATACCCTAg
11215 b TACTTCCTATTCTACACCC
11963 a AggACTCAACATACTAATCACA
12063 p ACCCTCATgTTCATACACCT
12501 a CAACAATATTCATATgCCTAg
12501 b ACAACAATATTCATgTgCCT
12705 a CTACTCATTTTCCTAATTACCA
12775 p TAggAATTATATCCTTCTTgC
12811 a TCATCAgTTgATgACACgCCC
13105 a ATgAgTAAgAAgACTCCTgC
13143 a TggATTAgTgggCTgTTTTC
13156 p CTAAgCATAgTgTTAgAgTTTg
13263 a TATTATgAgTCCTAgCTgACTTg
13563 a gCCTgAgCCCTgTCTAT
13928 a ggATTCTACCCTACCATCA
13928 b gATTCTACCCTAgCATCA
14343 p gTgggTgAAAgAgTATgATg
14476 a CTgTAgTATATCCAAAAACAACC
14893 a TgCATggCTAggAACAgTCCT
14893 b gCATggCTAggAATAgTCC
14927 a ATgAAAAggCggCTgAgg
14944 a gAgTgATgTgggCAATTgAT
14979 a AAggTAgCggATggTTCAgC
15067 a TATATTACggATCATTCCTCTAC
15346 a CACCTCCTATTCTTACACgAAA
15440 a ACgCCCTCggCCTACTTCT
15487 a TATTCTCACCTgACCTCCT
15497 a CCAgACCTCCTAAgCgAC
15524 a TTATACCCTAgCCgACC
15535 a CCAACCCCTTAAATACCCCTC
15535 b AACCCCTTAAACACCCCTCC
15826 p gTTggTATTAggATTAggATTgTT
15860 a gAgTATTTTgTTTTCAACTAgggA
15874 a AggCCCATTTgAgCATTTTgTT
15924 a gTTTTCATCTCCggCTTACAAg
16519 a TTCCTACTTCAgggCCATAAAg
16519 b TCCTACTTCAgggTCATAAAgC
NOTE.—Probes used for the ﬁrst set of hybridization.
a Purposes for probes are as follows: a, for detecting
polymorphism; b, for detecting wild type; p, for ver-
ifying PCR product; m, for detecting macrohaplogroup
M; and n, for detecting macrohaplogroup N.
signiﬁcantly reduced risk of T2DM (OR 0.55 [95%CI 0.40–
0.75], ), whereas those in haplogroup F or D5Pp .0002
tended to have an increased risk of T2DM. We performed
multiple-regression analysis of haplogroup N9a associated
with T2DM, with adjustment not only for age and sex but
also for BMI, systolic and diastolic blood pressure, total
cholesterol, triglycerides, and HDL cholesterol (table 9).
Even after adjustment for these parameters, logistic-re-
gression analysis demonstrated that haplogroup N9a is an
independent protective factor against T2DM for all Korean
subjects ( , OR 0.47 [95% CI 0.24–0.86]), KoreanPp .017
men ( , OR 0.36 [95% CI 0.14–0.83]), all JapanesePp .023
subjects ( , OR 0.57 [95% CI 0.32–0.98]), and Jap-Pp .048
anese women ( , OR 0.19 [95% CI 0.03–0.69]).Pp .030
We examined the relationships of the threemtSNPs that
were used for determination of the haplotype N9a to the
prevalence of T2DM in all populations, by multivariable
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Table 6. Probe Set B for Haplotyping
Position Purposea Sequence (5′r3′)
663 a gCTAATAgAAAggCCAggA
709 a gAACTCACTggAATggggAT
827 a AACAgCAgTgATTAgCCTTTA
1391 a TTTCATAAgggCTgTCgTAgT
1438 a AgCACTCTACTCTTAgTTTACT
1664 a AACTTAACTTgACCACTCTgA
2772 a gTTTAggACCTgTAggTTTg
2835 a TgCTCggAggTTgAgTTCTg
3243 a gATTACCgggCCCTgCCAT
3254 a TTTTAAgTTTTATgCAATTACCg
3421 a gCAAAggCCCCAACATTgTAg
3537 a CCCCgACCTTggCTCTC
3546 a CTTAgCTCTCACTATCgC
3696 a gCTCgCAgTgCgCCAATCAg
3714 a gAgATTgTTTgggCCACTgCT
3714 b gAgATTgTTTgggCTACTgCT
3759 a gCCATCATTCTACTgTCAACA
3970 a ggCTATgAAgAATAAggCgA
4538 a AAAAATCAgTgCgAACTTAgCg
4655 a gCggTTgCTTgTgTgAggA
4688 a TTgTTgAAgAggATggCTATT
4715 a TTATggTTCATTgCCCggAg
4820 a TTCTgAgTCCCAgAAgTTACCC
4850 a CTgACATCCggTCTgCTT
4883 a AACTAgCCCCTATCTCAAT
5127 a ATTCCTACTACTCgACTTAA
6005 a ggCTCgAATAAggAgACTTAgA
6018 a gCCTCCTTATTCgAACCgAgC
6146 a gCTTTggCAACTggCTAgTTC
6146 b gCTTTggCAACTgACTAgTTC
6179 a gTgCCCCCgATATAgCgTTT
6680 a CTCCCATATTgTAACCTACTACT
7600 a TAgACCTACTTgTgCTgC
7698 p CTgCTTCCTAgTCCTgTATgC
7861 a ACgAggTCAACgACCCCT
8188 a AAACTgTggTTTgCCCCACAgA
8200 a ACgATgggCATgAAgCTgTg
8251 a AgggTAAATACgggTCCTATT
8383 a TgggCCATACggTggTATTTAg
8450 a CACCCAACTAAAAATACTAAACAC
8453 a CCCAACTAAAAATATTAgACACA
8473 a AACTACCACCTACCCCCCTC
8701 a AgTgTTgTgTATggCTATCATT
8762 a CCTTAATCATTTTTACTgCCACAA
8856 a ATCCCCTTATgAgCAggCACA
8955 a CCCCATACTAgTTATCATCgAA
9090 a AgATgATAAgTgTggAgggA
9115 a ggATAgTCAgTAgAACTAgAATT
9242 a CTATCATATAgTAAAgCCCAgC
9833 a gACTTCACgTCATCATTggCT
9932 a CCgCCTgATACTgACATTT
10310 b TATTAgTggCAggTTAgTTgTT
10373 a TCCTTTTTgTAgTCATTCATA
10400 m TACCAATTCAgCTCAgTCT
10410 a TTTTgTTTAAACTATgTACCAAT
10454 a gACTCATTAAATTATgACAATCATA
11016 a gATAgTggTTCATTggATA
11017 a TgATAgTggTTCgCTgg
11696 a ATTATgAgAATgATTgCgC
11722 a TAATgAggATgTgAgTCCgT
12026 a CACTCACCCACCACgTTAACA
12085 a TCATACACCTATCTCCCATT
12092 a CTATCCCCCATTATCCTCC
12092 b TATCCCCCATTCTCCTCCT
12358 a gCACACTACTATAgCCACCCT
(continued)
Table 6. (continued)
Position Purposea Sequence (5′r3′)
12372 a AgCCACCCTAACCCTAACTTCC
12406 a ATCCTTACCACCCTCATTAACC
12753 a ACAACCTATTCCAgCTgTTC
12753 b ACAACCTATTCCAACTgTTC
13437 a TCAAAACCATACCCCTCAC
13512 a ggTTTCTACTCCAAggACCAC
13759 a TgTTTggAAgggggATgTgggg
13879 a CAAACTTAAAATAAAACCCCCA
13942 a ATCACACACCgCgCAAT
14287 a ATAATTTATgAAggggAggggT
14308 a TAATAgTgTAgggAgCTgAAT
14364 a AggTAggATTggTgTTgTgg
14914 a TgAggCgTCTggCgAgT
14996 a gAggCgCCATTggTgTgAAg
15047 a ACACATCggACgAAgCCTATA
15314 a gCTgCTAgggCTgTAATAATg
15422 a ACCCTTACTACACAgTCAAAgA
15508 a AggCgACCCAgATAATTAT
15508 b gCgACCCAgACAATTATAC
15850 a TCAATTAgggAgACggTTggTA
15883 a ACAAAATACTCAAATgAgCCTgT
NOTE.—Probes used for the second set of
hybridization.
a Purposes for probes are as follows: a, for detect-
ing polymorphism; b, for detecting wild type; p, for
verifying PCR product; and m, for detecting macro-
haplogroup M.
logistic-regression analysis with adjustment for age and
sex. All three mtSNPs were signiﬁcantly associated with
resistance against T2DM (5231GrA: , OR 0.54Pp .0001
[95% CI 0.40–0.74]; 12358ArG: , OR 0.62 [95%Pp .0026
CI 0.46–0.84]; and 12372GrA: , OR 0.59 [95%Pp .0005
CI 0.44–0.79]). The slight differences in the P values and
ORs among these mtSNPs are due to the occurrence of
the same replacement in different haplogroups (homo-
plasy or parallel mutations). The ﬁrst mtSNP (5231GrA)
was detected not only in haplogroup N9a but also in sub-
haplogroup D4k3. The second mtSNP (12358ArG) was
not detected in some of the subjects with haplogroup
N9a, probably because of a revertant substitution. In ad-
dition, the second mtSNP was also detected in subhap-
logroup D4b2b2 (tentative nomenclature). The third
mtSNP (12372GrA) was detected not only in haplogroup
N9a but also in subhaplogroup D4h. Thus, the combined
analysis of these three mtSNPs is essential for accurate
identiﬁcation of haplogroup N9a.
Japanese subjects in haplogroup F had a signiﬁcantly in-
creased risk of T2DM (OR 1.53 [95% CI 1.16–2.04],
), whereas those in haplogroup N9a tended toPp .0032
have a reduced risk for the disease. In particular, Japan-
ese women in haplogroup N9a had a signiﬁcantly reduced
risk of T2DM (OR 0.27 [95% CI 0.10–0.62], ),Pp .0042
whereas those in haplogroup F or A tended to have an
increased risk of T2DM.
Korean subjects in haplogroup N9a had a signiﬁcantly
reduced risk of T2DM (OR 0.43 [95% CI 0.24–0.77], Pp
), whereas those in haplogroup D5 or subhaplogroup.0048
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Table 7. Haplogroup Distribution in Controls and Patients with T2DM
Haplogroup
No. of Controls (%) No. of Patients with T2DM (%)
Japanese Korean Total Japanese Korean Total
F 96 (5.9) 61 (9.6) 157 (7.0) 112 (8.7) 71 (9.7) 183 (9.1)
B 196 (12.1) 98 (15.5) 294 (13.1) 152 (11.8) 113 (15.4) 265 (13.1)
A 102 (6.3) 46 (7.3) 148 (6.6) 100 (7.8) 63 (8.6) 163 (8.1)
N9a 79 (4.9) 40 (6.3) 119 (5.3) 41 (3.2) 19 (2.6) 60 (3.0)
M7a 115 (7.1) 9 (1.4) 124 (5.5) 92 (7.1) 17 (2.3) 109 (5.4)
M7b 68 (4.2) 18 (2.8) 86 (3.8) 45 (3.5) 21 (2.9) 66 (3.3)
G 188 (11.6) 43 (6.8) 231 (10.3) 141 (10.9) 65 (8.9) 206 (10.2)
D4a 152 (9.4) 38 (6.0) 190 (8.4) 111 (8.6) 32 (4.4) 143 (7.1)
D4b 109 (6.7) 29 (4.6) 138 (6.1) 83 (6.4) 54 (7.4) 137 (6.8)
D5 62 (3.8) 34 (5.4) 96 (4.3) 59 (4.6) 58 (7.9) 117 (5.8)
Othersa 450 (27.8) 217 (34.3) 667 (29.6) 353 (27.4) 219 (29.9) 573 (28.3)
Total 1,617 (100) 633 (100) 2,250 (100) 1,289 (100) 732 (100) 2,021 (100)
a Seventeen other haplogroups with low frequencies, including haplogroups N9b, Y, M10–M12, M7c,
M8a, Z, C, and D4d–D4n (except for D4f and D4i).
Table 8. Multivariate Logistic-Regression Analysis
of Haplogroups Associated with T2DM with
Adjustment for Age and Sex in Japanese and
Korean Populations
Population and Haplogroup P OR (95% CI)
Japanese and Korean subjects:
N9a .0002 .55 (.40–.75)
F .0114 1.34 (1.07–1.67)
D5 .0475 1.33 (1.00–1.76)
Japanese and Korean women:
N9a .0035 .43 (.24–.74)
Japanese subjects:
F .0032 1.54 (1.16–2.04)
N9a .0206 .63 (.43–.93)
Japanese women:
N9a .0042 .27 (.10–.62)
F .0163 1.79 (1.11–2.89)
A .0407 1.67 (1.02–2.72)
Korean subjects:
N9a .0048 .43 (.24–.77)
D5 .0483 1.60 (1.01–2.57)
D4b .0365 1.66 (1.04–2.81)
Korean men:
N9a .0031 .28 (.11–.62)
D4b .0019 3.55 (1.65–8.34)
NOTE.—Bold font indicates haplogroups with .P ! .005
D4b tended to have an increased risk of the disease. Korean
men in haplogroup N9a had a signiﬁcantly reduced risk of
T2DM (OR 0.28 [95% CI 0.11–0.62], ), whereasPp .0031
those in haplogroup D4b had a signiﬁcantly increased risk
of T2DM (OR 3.55 [95% CI 1.65–8.34], ).Pp .0019
We then examined whether the risk of T2DM with hap-
logroup N9a was related to age; systolic blood pressure; di-
astolic blood pressure; serum concentration of total cho-
lesterol, triglycerides and/or HDL cholesterol; FPG concen-
tration; or HbA1c level. None of the parameters, other than
FPG andHbA1c, showed signiﬁcant differencesbetweenthe
subjects with haplogroup N9a and those without it. The
FPG (mean SD) concentration was signiﬁcantly lower in
the individuals with haplogroup N9a than in those with
other haplogroups (6.5  3.0 mmol/liter vs. 7.1  3.1
mmol/liter, ). The HbA1c level was signiﬁcantlyPp .021
lower in individuals with haplogroup N9a than in those
with other haplogroups (6.1%  1.5% vs. 6.8%  1.9%,
).Pp .002
Discussion
We examined the relationships between T2DM and each
of 10 major mitochondrial haplogroups in a large-scale
association study in the Japanese and Korean populations.
Haplogroup N9a was signiﬁcantly associated with reduced
susceptibility to T2DM.
Mitochondrial haplogroup N9a has a great diversity in
the whole of China and Korea. In Japan, this haplogroup
was not detected in aboriginal Ainu and Ryukyuans but
only in mainland Honshu Japanese. This distribution
suggests that this haplogroup was derived from the new
immigrant, or Yayoi, people. These so-called mammoth
hunters who had adapted to extremely cold climates in
Siberiamigrated back to the northern part of China∼6,000
years ago. A part of this continental population immi-
grated into Japan through the Korean peninsula ∼2,900
years ago, and this immigration started the Yayoi period.
Haplogroup N9a was not detected in tooth DNA from the
remains of an individual from the Japanese Neolithic pe-
riod, known as the “Jomon” period, whereas N9a was re-
cently detected in the Yayoi remains at the Kuma-Nishioda
site in the northern part of Kyushu Island (K. Shinoda
[National Science Museum, Tokyo], personal communi-
cation). Thus, haplogroup N9a might be one of the mi-
tochondrial haplogroups that had been selected for ad-
aptation to cold climates. This historical character of
haplogroup N9a might be relevant to resistance against
T2DM by individuals who carry this haplogroup. These
hypotheses, however, must be examined further by func-
tional analysis of this haplogroup.
Most of the mtSNPs characteristic to haplogroup N9a
are synonymous substitutions, including 5231GrA and
12372GrA, which were used for the present genotyping.
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Table 9. Multivariate Logistic-Regression Analysis
of Haplogroup N9a Associated with T2DM
Population and Variable P OR (95% CI)
Japanese subjects:
Age .0003 .22 (.10–.49)
Sex .0088 1.38 (1.08–1.75)
BMI !.0001 .13 (.05–.35)
Triglycerides .0051 .07 (.009–.41)
HDL cholesterol .0255 14.5 (1.52–167)
Haplogroup N9a .0478 .57 (.32–.98)
Korean subjects:
Age !.0001 1,066 (321–3765)
BMI .0458 .42 (.18–.98)
Systolic blood pressure !.0001 .10 (.05–.21)
Triglycerides !.0001 .01 (.0009–.04)
Haplogroup N9a .0166 .47 (.24–.86)
Japanese men:
BMI .0019 .16 (.05–.51)
Triglycerides .0114 .08 (.01–.51)
Korean men:
Age !.0001 997 (184–6169)
BMI .0075 .19 (.05–.63)
Systolic blood pressure !.0001 .06 (.02–.21)
Triglycerides .0012 .007 (.0003–.12)
Haplogroup N9a .0233 .36 (.14–.83)
Japanese women:
Age .0028 .12 (.03–.47)
BMI .0158 .19 (.05–.72)
Haplogroup N9a .0298 .19 (.03–.69)
Korean women:
Age !.0001 273 (68.8–1186)
Systolic blood pressure !.0001 .14 (.05–.37)
Triglycerides !.0001 .001 (.0001–.02)
HDL cholesterol !.0001 .03 (.006–.14)
NOTE.—The analysis was adjusted for age, sex, BMI, systolic
and diastolic blood pressure, triglycerides, HDL and cholesterol.
Possible candidates for functional polymorphisms in the
noncoding region of this haplogroup are 150CrT and
338CrT. The 150CrT substitution was originally reported
to occur in Italian centenarians.26 Also, we reported this
substitution to be associated with healthy longevity in
both Finland and Japan.27 Thus, 150CrT might confer re-
sistance against T2DM. Among haplogroup N9a–speciﬁc
mtSNPs in the coding region, the mtSNP 12358ArG caus-
ing the T8A replacement in nicotinamide adenine dinu-
cleotide dehydrogenase subunit 5 (MTND5 [MIM 516005])
may be considered a potentially functional polymor-
phism. It seems possible that this T8A replacement might
inﬂuence the function of the ND5 and complex I. The
actual effect of the 12358ArG (ND5: T8A) on mitochon-
drial function remains to be examined. The metabolic
characteristics of individuals with haplogroup N9a with
both 150CrT and 12358ArG should be examined for bet-
ter understanding of the mechanisms underlying their re-
sistance against T2DM.
We detected a signiﬁcant association between haplo-
group N9a and a reduced risk of T2DM in all subjects (OR
0.55), and especially low ORs in Japanese women (0.27)
and Korean men (0.28) were obtained. Although we can-
not exclude the possibility that these associations resulted
from the reduced statistical power due to the decreased
sample size of subgroups, these sex- and region-speciﬁc
associations suggest that cultural factors, including nutri-
tional and social customs, modify the protective effect of
haplogroup N9a against T2DM. According to the Wallace
theory, adaptation to a cold climate might involve un-
coupling of electron transfer with ATP production, to in-
crease heat production.15,16 Thus, increasedmitochondrial
respiration and energy expenditure is essential tomeet the
ATP requirement. Such an uncoupling phenotype would
be protective against the development of obesity and, con-
sequently, T2DM. However, at present, we do not have
evidence that N9a is associated with lean body status. Al-
ternatively, the uncoupling phenotype might be related
to decreased mitochondrial oxidative stress, which might
in turn exert a protective effect against T2DM. Further
functional analysis of cybrids carrying haplogroup N9a
will be necessary to verify these hypotheses.
The mitochondrial genome variation is so large that a
given haplogroup may consist of various subhaplogroups
carrying unique and presumably functional mtSNPs. The
frequency of each subhaplogroup is sometimes only a few
percent. Therefore, large-scale association studies are nec-
essary for elucidating the impact of each subhaplogroup
on the susceptibility to various common diseases.
Although haplogroup F was signiﬁcantly associated
with a risk of T2DM in Japanese subjects (OR 1.53 [95%
CI 1.16–2.04], ), this association was not con-Pp .0032
ﬁrmed in Korean individuals. To explain this discrepancy,
we hypothesize certain interactions between mitochon-
drial haplogroups and nuclear polymorphisms and/or en-
vironmental factors. Alternatively, the difference in the
results between the Japanese and Korean subjects could
be ascribable to the difference in the subhaplogroup fre-
quencies between the two countries and to the functional
differences among certain subhaplogroups. Our success in
detecting a signiﬁcant association of haplogroupN9awith
resistance against T2DM in both Japanese and Korean in-
dividuals could be ascribable to the homogeneity of hap-
logroup N9a (coalescence age of 14,000 5,000 years ago)
compared with the heterogeneity of haplogroup F (coa-
lescence age of 47,000  9,000 years ago). Further bio-
medical and functional studies on mitochondrial poly-
morphisms should be conducted in conjunction with
human phylogenetic studies.
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